STOCK TITAN

Elicio Therapeutics, Inc. - $ELTX STOCK NEWS

Welcome to our dedicated page for Elicio Therapeutics news (Ticker: $ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company focused on transforming cancer treatment through cutting-edge immunotherapies. By leveraging its proprietary Amphiphile (AMP) platform, Elicio is developing vaccines and immunotherapies targeting aggressive cancers such as pancreatic, colorectal, and head and neck cancers.

The AMP platform uniquely targets and delivers immunogens directly to the lymphatic system, amplifying the body's immune response to fight cancer and prevent its recurrence. This innovative approach aims to unlock the full potential of the human immune system, resulting in enhanced anti-tumor functionality and long-term protective memory.

Recent achievements include:

  • The commencement of initial patient studies for its lead amphiphile vaccines targeting various cancers in early 2020.
  • Ongoing Phase 1 and Phase 2 trials for ELI-002, a novel cancer vaccine targeting mutant KRAS-driven tumors.
  • The publication of promising preclinical and clinical data which demonstrate the AMP platform's potential in enhancing T cell responses and eradicating solid tumors.

Financial updates reveal continued investment in clinical trials and research, with expenses reflecting the company's robust R&D initiatives. Partnerships with renowned institutions like the University of Texas MD Anderson Cancer Center further bolster Elicio's research capabilities.

Looking forward, Elicio plans to advance its development pipeline, including the ELI-002 7P Phase 2 trial as a monotherapy for patients with pancreatic ductal adenocarcinoma (PDAC). The company remains committed to pioneering new cancer treatments and improving patient outcomes.

Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX), a biotechnology company specializing in immunotherapies for cancer, announced on June 18, 2024, the issuance of 5,400 inducement stock options to two new employees. These options, granted on June 17, 2024, align with Nasdaq Listing Rule 5635(c)(4) and were approved by the board's Compensation Committee under the 2024 Inducement Incentive Award Plan. The options are priced at $7.98 each, reflecting the closing price on the grant date. Vesting occurs over four years with 25% vesting on the first anniversary of the employees' start dates, and the remaining vesting monthly thereafter, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Elicio Therapeutics revealed preliminary data from their AMPLIFY-7P Phase 1a study of ELI-002 7P at the ASCO 2024 Annual Meeting. The cancer vaccine candidate, targeting mKRAS-driven solid tumors, showed promising results. ELI-002 7P was well tolerated and induced a significant (~100x) mKRAS-specific T cell response in all enrolled patients.

Key findings included CD8+ and CD4+ responses in 66.7% of patients at the 4.9 mg dose, and tumor biomarker reductions in 71% of evaluable patients. Antigen-spreading, targeting non-immunizing tumor neoantigens, was observed in all patients at the 4.9 mg dose. The study supports further development, with the recommended Phase 2 dose being 10.0 mg AMP-CpG-7909 with 4.9 mg AMP-Peptides 7P.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
-
Rhea-AI Summary

Elicio Therapeutics (Nasdaq: ELTX) reported its Q1 2024 financial results and provided corporate updates on its lead cancer vaccine programs, ELI-002 2P and ELI-002 7P.

Q1 financial highlights include a net loss of $11.8 million, increased R&D expenses of $7.6 million, and G&A expenses of $2.7 million. Cash reserves stood at $11.9 million as of March 31, 2024.

ELI-002 2P data was published in Nature Medicine, showing promising immunogenicity and safety. ELI-002 7P is in Phase 2 trials, with preliminary Phase 1 data to be presented at ASCO in June 2024.

Upcoming milestones include completing Phase 2 enrollment for ELI-002 7P by Q4 2024 and providing updated data for ELI-002 2P in Q4 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.81%
Tags
Rhea-AI Summary
Elicio Therapeutics, a clinical-stage biotechnology company, will present new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study of ELI-002 7P at the 2024 ASCO Annual Meeting. The study focuses on patients with mKRAS-driven solid tumors and aims to stimulate an immune response against the seven KRAS mutations that drive 25% of all solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
conferences clinical trial
-
Rhea-AI Summary
Elicio Therapeutics, Inc. announces pipeline updates for investigational cancer vaccines at AACR Annual Meeting. ELI-002 shows promising results in mKRAS-driven cancers, inducing durable and potent T cell responses. Preclinical data on ELI-007 and ELI-008 also demonstrate strong immune responses targeting BRAF and p53 mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences clinical trial
-
Rhea-AI Summary
Elicio Therapeutics, Inc. reported financial results for 2023, highlighting progress in clinical trials and business development. Key points include poster presentations, ongoing Phase 2 trials, successful private placement, and financial data. The company's R&D expenses increased due to clinical trial initiation, while G&A expenses rose from operating as a public entity. Net loss decreased per share, primarily due to a reverse merger. Cash and cash equivalents grew by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Elicio Therapeutics, a biotechnology company, has entered into a subscription agreement to sell pre-funded warrants to purchase shares of its common stock in a private placement to GKCC, The gross proceeds are expected to be $6.0 million, with the net proceeds intended for the company's development pipeline and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28%
Tags
none
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced three upcoming poster presentations at the AACR Annual Meeting showcasing their innovative cancer vaccine candidates. The presentations will focus on the immunogenicity and efficacy of their AMP technology in targeting solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO, Robert Connelly, will be presenting the clinical-stage biotechnology company's pipeline of novel immunotherapies for cancer treatment. The presentation will be available via live webcast and on-demand for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Rhea-AI Summary
Elicio Therapeutics, Inc. announced promising preclinical data in Cancer Immunology Research, showing that their AMP immunotherapy platform enhanced TCR-T cell therapy, leading to complete eradication of solid tumors refractory to TCR-T cell monotherapy. The AMP treatment also promoted immune activation in lymph nodes, invigorating anti-tumor T cell immunity. The study demonstrated long-term protection against tumor recurrence and antigen spreading to additional tumor-associated antigens. Preclinical efficacy in solid tumors, including those with KRAS mutations, provides a strong rationale for the clinical advancement of a combination AMP immunotherapy strategy with TCR-T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags

FAQ

What is Elicio Therapeutics' core business?

Elicio Therapeutics focuses on developing innovative cancer immunotherapies using its proprietary Amphiphile (AMP) platform.

What is the AMP platform?

The AMP platform delivers immunogens directly to the lymph nodes to amplify the immune response against cancer.

What are Elicio's lead products?

Elicio's lead product is ELI-002, a cancer vaccine targeting mutant KRAS-driven tumors, currently in Phase 1 and Phase 2 trials.

What types of cancer does Elicio's AMP platform target?

Elicio's AMP platform targets aggressive cancers like pancreatic, colorectal, and head and neck cancers.

What recent progress has Elicio made in its research and development?

Elicio has started initial patient studies for its lead vaccines, published promising preclinical data, and is conducting Phase 1 and Phase 2 trials for ELI-002.

Who are some of Elicio's research partners?

Elicio has partnered with renowned institutions like the University of Texas MD Anderson Cancer Center.

What is the financial status of Elicio Therapeutics?

Elicio continues to invest in R&D with increased expenses due to ongoing trials and research, reflecting its commitment to developing innovative cancer treatments.

What is the significance of ELI-002 7P formulation?

ELI-002 7P targets seven common KRAS mutations, increasing potential patient coverage and aiming to reduce cancer recurrence.

What are the future plans for Elicio Therapeutics?

Elicio plans to continue advancing its development pipeline, including Phase 2 trials for ELI-002 7P, and exploring new immunotherapy candidates.

How does Elicio aim to enhance the immune system's cancer-fighting capabilities?

Elicio’s AMP platform directs therapeutic payloads to lymph nodes, optimizing immune responses to recognize and eliminate tumor cells.

Elicio Therapeutics, Inc.

Nasdaq:ELTX

ELTX Rankings

ELTX Stock Data

73.02M
5.39M
45.06%
5.31%
0.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON